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Abstract: Cell migration is a key process for the defense of pluricellular organisms against 
pathogens, and it involves a set of surface receptors acting in an ordered fashion to 
contribute directionality to the movement. Among these receptors are the integrins, which 
connect the cell cytoskeleton to the extracellular matrix components, thus playing a central 
role in cell migration. Integrin clustering at focal adhesions drives actin polymerization 
along the cell leading edge, resulting in polarity of cell movement. Therefore, small 
integrin-binding proteins such as the snake venom disintegrins that inhibit integrin-
mediated cell adhesion are expected to inhibit cell migration. Here we review the current 
knowledge on disintegrin and disintegrin-like protein effects on cell migration and their 
potential use as pharmacological tools in anti-inflammatory therapy as well as in inhibition 
of metastatic invasion. 
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1. Introduction  
Metastasis is one the major causes of death in patients with cancer. In order for a tumor to grow and 
metastasize, both tumor and endothelial cells must migrate and invade surrounding tissues [1,2]. 
Endothelial cell migration provides the blood supply that is essential to tumor cells. Once in the blood 
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vessels, tumor cells must adhere to the endothelium and escape to a new site [3], two processes that 
depend on their invasive abilities. Therefore, the blockage of both tumor and endothelial cell migration 
and invasion is an interesting approach for the treatment of cancer patients. The key receptors involved 
in cell migration are the integrins, which connect the cells to the extracellular matrix of the tumor 
microenvironment. Integrin blocking usually results in inhibition of cell migration and tumor 
angiogenesis [4]. Here we review the effects of disintegrins, a group of integrin-binding proteins found 
in snake venoms, in the cell adhesion process and their application in anti-cancer and anti-metastatic 
therapy. The effects of disintegrin on neutrophil migration will also be briefly described for a better 
illustration of the role of these proteins in cell migration. 
2. Integrins and Cell Migration  
Integrins are cell surface receptors that play critical roles in cell adhesion and migration. These 
proteins are heterodimers of transmembrane α- and β-subunits that connect the extracellular matrix 
(ECM) to the cell cytoskeleton. Cell binding by integrins to their cognate extracellular ligands, such as 
collagen, laminin and fibronectin, triggers intracellular signaling pathways that control cytoskeleton 
organization, cell polarity and force generation [5]. Integrin clustering at focal complexes drives actin 
polymerization along the leading edge of migrating cells, contributing to changes in cell shape and 
polarity [6]. Integrins are also involved in the regulation of matrix-degrading proteases, a key step for 
the invasive phenotype. There are several excellent reviews on the role of integrins in cell migration 
and invasion [6–8], and therefore, this subject will not be addressed in the present review. 
Furthermore, several studies have described the correlation between a malignant phenotype and an 
altered integrin distribution on tumor cell surfaces [9]. The role of integrins in metastatic dissemination 
is also very well documented [10,11], and is beyond the scope of this review.  
3. Angiogenesis 
The term angiogenesis usually defines the growth of sprouts from capillary blood vessels that 
depends on a delicate balance between pro- and anti-angiogenic factors. In mammals, physiological 
angiogenesis is restricted to specific situations, including growth, tissue regeneration and reproduction. 
In contrast, some angiogenesis-dependent diseases, such as tumor growth, age-related macular 
degeneration and atherosclerosis, have been described [12].  
Angiogenesis is primarily driven by tissue hypoxia that upregulates hypoxic factor-1 (HF-1) 
expression [7,13], which in turn induces vascular endothelial cell growth factor (VEGF) expression, a 
potent mitogen for endothelial cells [7,14]. Briefly, the angiogenic cascade includes degradation of 
basement membrane (BM) by matrix metalloproteases (MMPs) expressed by endothelial cells (EC), 
EC proliferation and tube formation, synthesis of a new BM, tube stabilization by pericytes and 
vascular smooth muscle cells and maturation into capillaries [15]. In addition, extracellular matrix 
degradation by MMPs plays a key role in the control of angiogenesis either by releasing VEGF from 
the ECM and facilitating EC migration, or by releasing angiogenesis inhibitors from larger 
extracellular matrix components such as endostatin from collagen XVIII [16,17], and angiostatin from 
plasminogen [15,18]. Angiogenesis is also influenced by integrins expressed on endothelial cells, 
vascular smooth muscle cells, fibroblasts, and platelets. These cells process signals from their Toxins 2010, 2  
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microenvironment and respond by altering their cell-cell and cell-matrix adhesion, which allows 
migration and vascular remodeling over a period of days to weeks [19].  
On the other hand, tumor angiogenesis is not particularly effective. Tumor vessels are structurally 
and biologically different with leaky characteristics that facilitate tumor cell dissemination by blood or 
lymphatic vessels [4,20]. Unlike in quiescent EC, the αvβ3 integrin is highly expressed by tumor EC, 
which helps the binding of new ECs to the provisional matrix components, including vitronectin and 
fibronectin that are deposited in the tumor microenvironment [4]. Accordingly, small integrin binding 
proteins have been tested for their ability to inhibit tumor angiogenesis. We will review the work that 
has been done with snake venom disintegrins in this field. 
4. Disintegrins from Snake Venoms 
Snake venom disintegrins are mostly derived from proteolytically processed precursor forms having 
a metalloprotease domain, named the snake venom metalloproteases (SVMPs). Members of this 
protein family have been classified according to their multi-domain structure into P-I, P-II and P-III 
classes [21]. Members of the P-I class are formed by a metalloprotease domain only while P-II proteins 
have a metalloproteinase and a disintegrin domain. P-III proteins have an additional cysteine-rich 
domain following the disintegrin region and in some cases, a lectin domain [22]. These last two classes 
(P-II and P-III) can be subdivided further according to the proteolytic processing of their domains and 
their ability to form dimeric structures [23]. Based on this classification, processed RGD-disintegrins 
are derived from the P-IIa class, while homo- and heterodimeric disintegrins are released in general 
from SVMPs belonging to the P-IId and P-IIe classes, respectively. P-III SVMPs originate   
the disintegrin-like proteins (DC, for Disintegrin, Cys-rich proteins) formed by covalently   
linked-disintegrin-like and Cys-rich domains [21]. By means of phylogenetic analysis,   
Calvete  et al. [24] provided strong evidence that the diversity of disintegrins could be due to an 
accelerated evolution of surface-exposed residues with the inference that the RGD motif is the 
ancestral integrin-recognition motif from which other disintegrins have emerged via single-base 
substitutions to generate KGD-, MGD-, WGD-, and VGD-integrin binding motifs as well as others. 
The diversity of the integrin-binding loop, along with other conserved residues among disintegrin 
molecules, gives rise to different integrin specificities (Table 1). However, disintegrin structural 
complexity does not derive only from venom genomic structure and transcriptional regulation events 
but also from post-translational modifications that could be responsible for dimerization and disulfide 
bonding as previously suggested [21]. 
DC proteins are usually found in a processed form in snake venoms without the catalytic domain 
but they are not further separated into independent proteins due to a disulfide bond that connects both 
domains. The active RGD loop of P-II-derived disintegrins is modified into a cysteine-contained loop 
(D/ECD) in the DC proteins [25]. It has been recently suggested that distinct disulfide pairing strongly 
contributes to the conformation of the D domain, which could consequently influence the binding 
properties and specificities of DC proteins [26]. Depending on the disulfide pairing, the D domain may 
assume at least two types of conformation, a C-shaped or an I-shaped scaffold; the former was 
suggested to play a key role in substrate recognition by the catalytic domain [27]. The D domain also 
has adhesive properties to some proteins such as collagen I, as recently demonstrated.  Toxins 2010, 2  
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Integrin binding ability is apparently more related to the Cys-rich domain [28,29] which was also 
shown to bind von Willebrand factor therefore helping substrate targeting for proteolysis by the 
metalloprotease domain [30]. In addition, the hyper-variable region (HVR), considered the major 
structurally distinct region among the P-III SVMPs and suggested to play a key role in target selection 
due to its protein-protein adhesive properties, is located in the Cys-rich domain [29]. The importance 
of HVR was recently evidenced for two elapidic SVMPs from Naja atra venom. Atragin, a SVMP 
with a C-shaped D domain, but not its homolog K-like, which has an I-shaped scaffold, inhibits the 
migration of both mouse fibroblasts and Chinese hamster ovary CHOK1 cells [26]. Synthetic peptides 
from the HVR of both atragin and K-like proteins showed similar results, since only the peptide from 
atragin HVR inhibited cell migration toward fibronectin [26]. 
Disintegrins and DC proteins are rich in Cys residues, which are mainly involved in disulfide 
bonds, resulting in proteolysis-resistant molecules. This is a crucial feature for a sustained half-life in 
the blood. DisBa-01, a recombinant disintegrin from Bothrops alternatus venom, could be detected up 
to 6 h hours after i.p. injection in mice [31]. Despite the high content of disulfide bonds, RGD-
disintegrins can be produced in an active form in bacteria [32,33], thus allowing the production of 
large quantities as needed for in vivo tests. Recombinant DC proteins are more difficult to express in 
an active form in bacteria. However, the production of Cys-rich domains from P-III SVMPs in active 
form has been reported [29].  
5. Effects of Disintegrins on Leukocyte Migration 
Neutrophils can be recruited from blood circulation toward sites of inflammation due to signals 
from injured tissues. To reach these sites, neutrophils must express new receptors, including some 
integrins, on their cell surface that will allow their adhesion to the endothelium and subsequent 
migration into tissues [34]. In addition to several constitutively expressed integrins such as αMβ2, αvβ3 
and  α9β1, these cells express α2-,  α3-,  α4-, and α5β1 integrins upon activation [35,36], triggering 
integrin-signaling pathways that mediate actin polymerization, cytoskeletal organization, spreading 
and migration [37]. Accordingly, disintegrins were first tested as integrin inhibitors of neutrophil 
migration as potential anti-inflammatory candidates. However, the results showed that integrin-binding 
by disintegrins could also activate neutrophils and protect these cells from apoptosis [38,39], 
demonstrating the complexity of disintegrin effects.  
Coelho et al. [38] first demonstrated the dual effect of the monomeric RGD-disintegrin jarastatin 
(JT), from Bothrops jararaca venom, on neutrophil chemotaxis. Jarastatin inhibited neutrophil 
migration toward fMLP, IL-8 and jarastatin itself in a concentration-dependent manner. However, JT 
also induced neutrophil chemotaxis when used as chemoattractant [38]. In addition, it was 
demonstrated that this disintegrin induced several downstream integrin-mediated signaling events such 
as actin polymerization, activation of focal adhesion kinase (FAK) and extracellular-regulated kinase-2 
(erk-2) nuclear translocation, which resulted in a delay of spontaneous neutrophil apoptosis [40]. JT 
also inhibited neutrophil migration in vivo after intraperitoneal carrageenan injection [38]. Ocellatusin, 
an RGD-disintegrin from Echis ocellatus venom, also strongly induces neutrophil chemotaxis [41]. 
Later, the same group demonstrated that EC3, a heterodimeric MLD-disintegrin from Echis carinatus 
venom, also inhibited neutrophil chemotaxis and activated FAK and phosphoinositide 3-kinase (PI3K); Toxins 2010, 2  
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however, in contrast to JT, EC3 inhibited Erk-2 translocation and had a pro-apoptotic effect [39]. 
Antibody competition assays showed that JT and EC3 effects are mediated by different neutrophil 
integrins. JT binds preferentially to αMβ2 while EC3 is a ligand for α9β1 in neutrophils [39,42]. In 
contrast, it has been recently shown that activation of α9β1 integrin by VLO5, a dimeric disintegrin 
from Vipera lebetina obtusa venom [43], inhibits neutrophil spontaneous apoptosis by up-regulating 
the expression of anti-apoptotic proteins Bcl-xL and by increasing the degradation of pro-apoptotic 
protein Bad [36]. The two dimeric disintegrins EC3 and VLO5 are an interesting example of how 
subtle the structural differences that lead to distinct biological effects can be. Both disintegrins are very 
similar and have the VGD motif on the A-subunit while the B-subunit has a single amino acid 
replacement N-terminally to the MLD adhesive motif. This MLD motif has been suggested to be 
responsible for the different binding specificities and biological effects. An alanine residue in EC3 
(AMLD) is replaced in VOL5 by a threonine residue (TMLD), which could result in distinct affinities 
and effects, despite their binding to the same integrin receptor [36]. 
RGD-disintegrins were also demonstrated to activate human T lymphocytes via integrin signaling 
[44]. Flavoridin, from Trimeresurus flavoviridis, kistrin, from Agkistrodon rhodostoma, and echistatin, 
from Echis carinatus venoms, which all bind to α5β1 and αvβ3, induced T cell proliferation and CD69 
expression in parallel with FAK and PI3K activation and NF-κB nuclear translocation [44].  
Alternagin-C (ALT-C), an ECD-containing disintegrin-like protein from Bothrops alternatus 
venom induced neutrophil effects similar to those of JT [45]. It inhibited neutrophil migration in a 
concentration-dependent fashion despite being itself chemotactic to this cell type. ALT-C also induced 
significant cytoskeleton dynamic changes with polymerization of F-actin, FAK and PI3K activation, 
and erk-2 translocation as well. These effects were reproduced by an ECD-containing peptide derived 
from the ALT-C primary sequence [45,46]. Interestingly, ALT-C was demonstrated to be an inhibitor 
of α2β1 integrin-mediated cell adhesion to collagen I. Jararhagin-C, the released DC domain from the 
SVMP jararhagin isolated from Bothrops jararaca venom, also induced in vivo leukocyte rolling after 
topical application on murine cremaster muscle. These observations together confirm the key role for 
the α2β1 integrin in neutrophil migration [47]. 
The complexity of the DC proteins was further demonstrated by the work of Menezes and   
co-authors, showing that the recombinant Cys-rich domain of HF3 metalloprotease from Bothrops 
jararaca venom is able to activate leukocyte rolling in the microcirculation [29]. This protein was 
expressed in bacteria without the disintegrin-like domain thus providing convincing evidence of that 
DC proteins activity resides on the Cys-rich region. In addition, synthetic peptides derived from the 
HVR region of the Cys-rich domain of HF3 reproduced the same effect, which was also inhibited by 
anti-αMβ2 antibodies, confirming the integrin-mediated activity of the C domain in leukocytes.  
6. Effects of Disintegrins on Endothelial Cell Migration and Angiogenesis 
Triflavin from Trimeresurus flavoviridis venom was one of the first RGD-disintegrins shown to 
inhibit angiogenesis both in vitro and in vivo [48]. Triflavin (0.4 μM) strongly inhibited EC migration 
toward vitronectin and fibronectin nearly thirty orders of magnitude greater than the anti-αvβ3 
monoclonal antibodies [48]. Triflavin was also more effective in inhibiting TNF-α-induced 
angiogenesis in the chicken chorioallantoic membrane (CAM) assay. Similar results were obtained Toxins 2010, 2  
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with another RGD-disintegrin, rhodostomin, from Agkistrodon rhodostoma venom, which inhibits 
endothelial cell migration, invasion and tube formation evoked by bFGF in matrigel both in vitro and 
in vitro [49]. Rhodostomin effects were inhibited by anti-αvβ3 but not by anti-αvβ5 antibodies, thus 
supporting the hypothesis that the effects of RGD-disintegrins are mediated by blockade of the 
vitronectin receptor. 
Native or recombinant contortrostatin (CN), a homodimeric RGD-disintegrin from Agkistrodon 
contortrix contortrix venom, is another example of anti-angiogenic disintegrin as demonstrated by 
several in vitro and in vivo models [50–52]. Liposomal delivery of CN has proven to be effective as an 
anti-angiogenic and anti-tumor agent in human ovarian and breast cancer animal models [52]. Similar 
results were obtained with vicrostatin, a quimeric recombinant CN variant, which was also 
demonstrated to induce apoptosis in tubulogenic HUVEC seeded between two matrigel layers [53]. A 
monomeric recombinant RGD-disintegrin from Bothrops alternatus venom, DisBa-01, produces 
similar effects in the matrigel plug model in nude mice [33]. In addition to inhibition of EC migration, 
saxatilin, an RGD disintegrin from Gloydius saxatilis also inhibited the migration of vitronectin-
induced smooth muscle cells [54,55]. 
However, the complexity of disintegrin specificity and the process of migration do not allow for the 
conclusion that blocking the vitronectin receptor is sufficient for inhibiting cell migration. Echistatin, 
but not eristostatin (two short RGD-disintegrins), inhibits in vivo angiogenesis in the CAM assay [56]. 
There are at least three KTS-disintegrins that inhibit α1β1 integrin binding to its cognate ligands, 
collagen I and IV (Table 1) [57,58], and also inhibit EC migration toward these substrates [59]. 
Lebestatin is an example of a KTS-disintegrin isolated from Macrovipera lebetina that inhibits EC 
migration and VEGF-induced in vivo angiogenesis [59]. The presence of a WGD motif in CC8, a 
heterodimeric disintegrin from Echis carinatus, increases its inhibitory effect on αvβ3 and α5β1 
integrins [60].  
There are few reports regarding the effects of ECD-disintegrins on endothelial cell migration. 
Acurhagin-C, an ECD-disintegrin-like protein from Agkistrodon acutus venom, dose-dependently 
blocked HUVEC migration toward a vitronectin-coated membrane. Furthermore, acurhagin-C elicited 
endothelial anoikis via disruption of the αvβ3/FAK/PI3K survival cascade and subsequent initiation of 
the procaspase-3 apoptotic signaling pathway [61]. Similarly, ALT-C also inhibits EC migration both 
in vitro and in vivo [62,63].  
7. Effects of Disintegrins on Tumor Cell Migration 
The ability of most snake venom disintegrins to inhibit cell adhesion has stimulated scientists to 
study these proteins as inhibitors of tumor cell dissemination. A volume of papers dealing with this 
subject can be found in the literature, most on RGD-disintegrin effects (Table 1). Morris et al. [64], 
were one of the first investigators to test eristostatin, an RGD-disintegrin from Eristocophis 
macmahoni, on individual metastasis steps such as cell arrest, extravasation and migration. Eristostatin 
treatment did not prevent tumor cell extravasation or migration [55]. However, it was shown later that 
eristostatin inhibited melanoma cell motility, an effect mediated by fibronectin-binding integrins [56]. 
Interestingly, this disintegrin, contrary to other RGD-disintegrins, did not inhibit angiogenesis, as 
stated before [56].  Toxins 2010, 2  
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DisBa-01, an αvβ3 integrin-blocking RGD-disintegrin, inhibits not only endothelial cell in vivo 
migration [33] but also the in vitro migratory ability of fibroblasts and two tumor cell lines in a 
concentration-dependent fashion (Figure 1A). These three cell lines were compared in terms of integrin 
content by flow cytometry. Interestingly, the content of αvβ3 is relatively low in these three cell lines 
compared to the amount of α2β1. Among the tested cell lines, human fibroblasts are the most sensitive 
to DisBa-01 and, coincidently, also have the highest content of αvβ3 integrin (Figure 1B). However, a 
change in receptor density after disintegrin treatment is a possibility that cannot be excluded. 
Figure 1. A (top) Effects of Disba-01 on the migration of three different cell lines. The 
cells were plated on the migration inserts in the presence of increasing concentrations of  
DisBa-01 for 22 h. Migration was expressed as a percentage of the control (100%). Cells 
were counted with a microscope (ten random fields per experiment). Results represents  
mean ± standard error of three individual experiments, *** p < 0.0001. B (bottom) Integrin 
profile of the cells tested in the migration assay using DisBa-01. Fibroblasts (FH) express 
αvβ3, αvβ5, α6, and β1. MDA-MB-231 breast tumor cells express αvβ3, αvβ5, α6, α2, and β1.  
DU-145 prostate tumor cells express more αvβ5,  α6,  α2,  β1, and less αvβ3 and α4. The 
presence of integrin receptors on the cell surface was determined by flow cytometry with 
FITC-anti-αvβ3, αvβ5, α6, α4, α2, β1 and αv subunit integrin antibodies. 
 
 
 Toxins 2010, 2  
 
 
2613
Table 1 summarizes the effects of several disintegrins and DC proteins on tumor-related cell 
migration in different systems and the range of tested concentrations. The diversity of in vitro and  
in vivo assays makes a quantitative comparison difficult. Most tested proteins are effective in a 
micromolar range for in vivo assays while nanomolar concentrations are used in in vitro tests. From the 
data in the literature, it seems that disintegrins are general inhibitors of cell migration and invasion, 
despite being unspecific ligands, such as the RGD-disintegrins, or integrin-specific binding proteins, 
such as the KTS-disintegrins (Table 1). The disintegrin-like, Cys-rich proteins may also be included as 
integrin blockers of cell migration. Since integrin receptors are also quite indiscriminate as they 
support cell adhesion to several substrates, it seems highly reasonable that the general RGD-disintegrin 
scaffold of the integrin-binding motif could be employed as a prototype for drug design for new anti-
metastatic therapies via blocking both tumor cell adhesion and tumor angiogenesis. In fact, at least two 
antagonists of platelet αIIbβ3 fibrinogen receptor that are currently being used in anticoagulant therapy 
(eptifibatide and aggrastat) were based on a snake venom disintegrin structure. 
Table 1. Structural determinants, preferential integrin and the effects of disintegrins and 
disintegrin-like proteins on migration-dependent tumor cell activities. 
Disintegrin Structure 
Adhesive 
motif 
Preferred 
integrin 
Cognate ligand Relevant inhibitory activity (conc.*)  Ref.
salmosin 2  monomeric medium  RGD  αvβ3 Vn  angiogenesis  **  (5  μg) [65] 
saxatilin monomeric  medium  RGD  αvβ3  Vn  angiogenesis (100 nM)  [54] 
jarastatin monomeric  medium  RGD  αvβ3, α5β1, αMβ2 Vn, Fn, ICAM-1 melanoma lung metastasis ** (1 μM) [66] 
flavoridin monomeric  medium RGD  α5β1  Fn  melanoma lung metastasis ** (1 μM) [66] 
kistrin monomeric  medium  RGD  αvβ3  Vn  melanoma lung metastasis **( 1 μM) [66] 
colombistatin monomeric  medium  RGD  nd  Fn  tumor cell migration (IC50 = 1.8 μM) [67] 
trigramin monomeric  medium  RGD  αvβ3 Vn  bone  metastasis  **(100  μg/ml) [68] 
DisBa-01 
eristostatin 
monomeric medium 
monomeric short 
RGD 
RGD 
αvβ3 
αIIbβ3 
Vn 
Fg 
melanoma metastasis **(2 mg/Kg) 
melanoma metastasis (25 μg) 
[33] 
[69] 
echistatin 
triflavin 
monomeric short 
monomeric short 
RGD 
RGD 
αvβ3 
αvβ3 
Vn 
Vn 
osteoclast migration (10 nM) 
angiogenesis **(0.1–0.4 μM) 
[70]  
[48] 
contortrostatin 
alternagin-C 
leberagin-C 
acurhagin-C 
Homodimeric 
monomeric D/C 
monomeric D/C 
monomeric D/C 
RGD 
ECD 
ECD 
ECD 
α5β1, αvβ5 
α2β1 
αvβ3, α5β1, αvβ6 
αvβ3 
Fn 
collagen I 
Vn, Fn 
Vn 
tumor angiogenesis **(60 μg/day) 
angiogenesis **(1 μM) 
melanoma cell adhesion (100 nM) 
angiogenesis **(0.4 μM) 
[71] 
[63] 
[72] 
[61] 
VLO5 heterodimeric VGD,  MLD  α9β1  TN, VCAM   glioblastoma growth (100 μg/ml) [73] 
obtustatin monomeric  short  KTS  α1β1  collagen IV  angiogenesis **(0.4 μg/μl) [74] 
viperistatin 
lebestatin 
monomeric short 
monomeric short 
KTS 
KTS 
α1β1 
α1β1 
collagen IV 
collagen IV 
melanoma cell transmigration (1–4 μM) 
angiogenesis **(0.1–0.5 μg/embryo) 
[75] 
[59] 
Legend: Vn, vitronectin; Fn, fibronectin; Fg, fibrinogen; TN, tenascin; ICAM-1, intercellular cell adhesion 
molecule-1; VCAM, vascular cell adhesion molecule. * Effective inhibitory concentration; ** in vivo assays. 
 
It has been suggested that the adhesive properties of the disintegrin-like, Cys-rich proteins could be 
primarily due to the Cys-rich domain, which was demonstrated to bind vWF [30,76]. Interestingly, half 
of integrin α subunits possess a von Willebrand factor A domain (also called I domain), which is in 
close proximity to the ligand-binding site [77]. Therefore, it is possible that the DC proteins could bind Toxins 2010, 2  
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to the integrins presenting this domain, thus increasing specificity. However, this possibility remains to 
be demonstrated. 
8. ADAMs and Cell Migration 
Studies of the snake venom disintegrin effects on cell migration were conducted in parallel with 
those on mammalian ADAMs. The ADAM (A Disintegrin And Metallopeptidase) family of proteins 
comprises a snake venom-homolog group of multidomain proteins that play important roles in many 
biological processes, including cell migration, development and fertilization [78–82]. Structurally, the 
ADAM disintegrin and Cys-rich domains are more related to the DC proteins from SVMPs than the 
RGD-disintegrins. The disintegrin and Cys-rich domains of ADAM9 were shown to increase 
keratinocyte migration and MMP-9 activity in a wound healing in vitro model, an effect mediated by 
β1 integrin receptors [83]. More recently, it was reported that knockout animals for ADAM9 showed 
accelerated wound repair compared to controls, due apparently to the increased migration of 
keratinocytes [84]. Interestingly, ADAM15, the unique RGD-disintegrin among the ADAMs, 
suppressed CHO cell motility by inducing integrin α5β1 expression on the cell surface, thereby 
enhancing cell adhesion [85]. Additionally, it was demonstrated that the recombinant disintegrin 
domain of ADAM15 completely inhibited endothelial cell migration and tube formation in a three-
dimensional fibrin gel [86]. More recently, the recombinant disintegrin domain of ADAM9 was 
demonstrated to strongly inhibit MDA-MB-231 breast tumor cell invasion on matrigel in vitro [87], 
thus suggesting a key role for this domain in the process of tumor cell invasion. Moreover, ADAM9 
silencing completely inhibited breast tumor cell in vitro invasion on matrigel [88]. Recently, it was 
demonstrated that in vivo gene silencing of ADAM9 reduced tumor metastasis [89]. These studies and 
others in the field with different ADAMs [90–92], reinforce the importance of integrins as critical 
targets for drug design, as well as the potential of disintegrins as lead pharmaceutical compounds. 
9. Concluding Remarks 
Cell adhesion and migration are crucial steps for metastasis development, processes in which the 
integrins are strongly involved. Snake venom disintegrins have been shown to inhibit metastasis by 
effectively blocking integrin activities. Apparently, the lack of specificity of these molecules seems to 
be a positive factor in inhibition of cell adhesion. However, tumor cells have demonstrated their ability 
to overcome FAK-dependent anchorage and the subsequent anoikis by activating parallel routes such 
as those mediated by Src and p130CAS [4,93]. It would be interesting to determine if disintegrins can 
also block these pathways in order to inhibit tumor metastasis completely. A search for new molecules 
that impair other survival mechanisms of tumor cells may be necessary to achieve improved results in 
anti-metastatic therapy. Also fascinating is the possible ability of disintegrins to interfere with 
collective cell migration, which differs from the single cell process mainly by the fact that cells remain 
coupled by cell-cell junctions while moving. This process depends on simultaneous coordination of 
cell polarization and was demonstrated to be relevant for cancer invasion and metastasis [94–96]. The 
potential for disintegrins to inhibit collective tumor cell migration remains to be determined. Toxins 2010, 2  
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